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ABSTRACT
Romosozumab is abone-formingagentwith adual effect of increasingbone formationanddecreasingbone resorption. In FRActure study
inpostmenopausalwoMenwithostEoporosis (FRAME), postmenopausalwomenwithosteoporosis received romosozumab210mgs.c. or
placebo oncemonthly for 12months, followed by denosumab 60mg s.c. once every 6months in both groups for 12months. One year of
romosozumab increased spine and hip BMD by 13% and 7%, respectively, and reduced vertebral and clinical fractures with persistent
fracture risk reductionupon transition to denosumabover 24months. Here,we further characterize the BMDgainswith romosozumabby
quantifying the percentages of patients who responded at varyingmagnitudes; report themean T-score changes from baseline over the
2-year study and contrast these results with the long-term BMD gains seen with denosumab during Fracture REduction Evaluation of
Denosumab in Osteoporosis every 6 Months (FREEDOM) and its Extension studies; and assess fracture incidence rates in year 2, when all
patients received denosumab. Among 7180 patients (n¼ 3591 placebo, n¼ 3589 romosozumab), most romosozumab-treated patients
experienced 3% gains in BMD from baseline at month 12 (spine, 96%; hip, 78%) compared with placebo (spine, 22%; hip, 16%). For
romosozumabpatients,meanabsolute T-score increases at the spine andhipwere 0.88 and0.32, respectively, at 12months (placebo: 0.03
and0.01) and1.11 and0.45 at 24months (placebo-to-denosumab: 0.38 and0.17),with the2-year gains approximating theeffect of 7 years
of continuous denosumab administration. Patients receiving romosozumab versus placebo in year 1 had signiﬁcantly fewer vertebral
fractures in year 2 (81% relative reduction; p< 0.001), with fewer fractures consistently observed across other fracture categories. The data
support the clinical beneﬁt of rebuilding the skeletal foundationwith romosozumabbefore transitioning toantiresorptive therapy.©2018
The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.
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Introduction
Romosozumab is a monoclonal antibody that binds andinhibits sclerostin. Through sclerostin inhibition, this bone-
forming agent has the dual effect of increasing bone formation
and decreasing bone resorption,(1,2) resulting in rapid and large
gains in bone mass and density and improved bone struc-
ture.(3–5) In the phase 3 FRActure study in postmenopausal
woMen with ostEoporosis (FRAME), 1 year of romosozumab
treatment reduced new vertebral and clinical fracture risk
compared with placebo in postmenopausal women with
osteoporosis, with relative risk reductions (RRRs) of 73%
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(p< 0.001) and 36% (p¼ 0.008), respectively, and was well
tolerated.(6) Romosozumab also resulted in large gains in BMD,
with mean percent increases over placebo of 13% at the lumbar
spine and 6% at the total hip (both p< 0.001) after 1 year.
In FRAME, all patients received denosumab in the second year
and, over the cumulative 2-year study period, treatment with
romosozumab led to continuous fracture risk reduction, with
BMDdifferences betweengroups atmonth 12 overallmaintained
at month 24.(6) At 24 months, there was a 75% relative reduction
in the risk of new vertebral fracture in patients who received
romosozumab followed by denosumab compared with those
who receivedplacebo followed by denosumab (p< 0.001), with a
persistent beneﬁt across other fracture categories as well.
Although the primary analysis was designed to assess the
sequence of romosozumab-to-denosumab versus placebo-to-
denosumab, the results suggested a persistent beneﬁt during the
denosumab period in the second year from the large bone mass
accrual achieved with romosozumab in the ﬁrst year; the current
analysis aimed to explore this concept further.
This analysis further characterized the BMD gains observed
during the FRAME study by comparing the proportion of
patients achieving BMD gains of varying magnitudes at the
lumbar spine and total hip in response to romosozumab
compared with placebo during year 1. It also summarized
absolute T-score changes from baseline over the 2-year course
of the study, after each group received romosozumab or
placebo and after both groups received 1 year of denosumab.
We placed the changes in BMD observed with romosozumab
and then denosumab in the context of changes seen in the
Fracture REduction Evaluation of Denosumab in Osteoporosis
every 6 Months (FREEDOM) and its Extension studies with
denosumab alone, during which continued BMD gains were
observed over 10 years of treatment, to qualitatively assess the
magnitude of BMD changes with romosozumab relative to the
only osteoporosis treatment shown to increase BMD over such
an extended period.(7) We further evaluated the clinical
importance of the BMD gains from 1 year of romosozumab by
comparing fracture incidence rates observed in the second year
of the study, during which all patients received denosumab—a
time when differences in fracture rates reﬂected the impact of
having initially received romosozumab versus placebo before
transitioning to denosumab.
Patients and Methods
Study design
This secondary, post-hoc analysis was based on FRAME
(ClinicalTrials.gov, NCT01575834), a phase 3, international,
randomized, double-blind, placebo-controlled, parallel-group
trial in postmenopausal women with osteoporosis.
FRAME has been described in detail elsewhere.(6) Women
were eligible for this study if they were between 55 and 90 years
old, had a T-score of –2.5 to –3.5 at the total hip or femoral neck,
and at least two vertebrae in the L1 through L4 region and at
least one hip that could be evaluated by DXA. Exclusion criteria
have been described in detail.(6)Womenwere randomized 1:1 to
receive romosozumab 210mg s.c. or placebo once monthly
(QM) for 12 months, after which both groups transitioned to
denosumab 60mg s.c. once every 6 months (Q6M) for an
additional 12 months. All patients received calcium and vitamin
D supplementation throughout the study. The coprimary
endpoints of the study were the subject incidence of new
vertebral fracture through month 12 and through month 24;
secondary endpoints included subject incidence of other
fracture types. In FRAME, BMD was measured at the lumbar
spine and total hip in all patients at months 12 and 24, and
additionally at months 6 and 18 in a subset of 128 patients (66
romosozumab, 62 placebo) in a DXA substudy; BMD was also
measured at the lumbar spine and total hip at month 6 in an
additional 162 patients from Argentina (92 romosozumab, 70
placebo; assessed to meet in-country requirements).
The current analysis also used BMDdata fromFREEDOMand its
Extension. FREEDOM, the pivotal fracture study for denosumab,
has been described.(8) In that study, postmenopausal women
aged 60 to 90 years with a T-score at the lumbar spine or total hip
 –2.5 were randomized 1:1 to receive denosumab 60mgs.c.
Q6M or placebo for 3 years; patients who missed 1 dose of
investigational product were eligible to enter the open-label
Extension, during which all patients received denosumab
60mgs.c. Q6M for up to an additional 7 years.(7) In FREEDOM
and its Extension, BMDwasmeasured in all patients atmonths 12
and 24 (total hip) and months 36, 48, 60, 72, 96, and 120 (lumbar
spine and total hip), and additionally at months 6, 12, and 24
(lumbar spine and total hip) in a subset of 441 patients from
FREEDOM (232 denosumab, 209 placebo) in a DXA substudy.
The FRAME trial was conducted in accordance with the World
Medical Association Declaration of Helsinki–Ethical Principles for
Medical Research InvolvingHuman Subjects. The trial protocol was
approved by an ethics committee or institutional review board at
each trial center. Patients provided written informed consent.
Outcome measures
A responder analysis assessed the percentage of patients with a
percent change from baseline in BMD by DXA of varying
magnitudes (ie,3%,6%, and10%; chosen empirically, with
3% representing the approximate least signiﬁcant change) at
the lumbar spine and total hip at month 12, as well as patients
who did not have BMD increases (0%); mean absolute change
from baseline in lumbar spine and total hip BMD T-scores during
the ﬁrst 2 years in patients from FRAME and throughout 10 years
in patients from FREEDOM and FREEDOM Extension; and subject
incidence of fractures in the second year of FRAME, including
new vertebral, clinical, major osteoporotic, nonvertebral, major
nonvertebral, and hip fractures.
Statistical analysis
For BMD response in FRAME, based on percent change from
baseline at month 12, missing BMD values were imputed by
carrying forward the lastpostbaselineobservation. ForBMDT-score
changes frombaseline, comparisons between treatment groups in
FRAME were based on a linear mixed effect repeated measures
model, adjusting for treatment, visit baseline value, age (<75
versus75 years), and prevalent vertebral fracture (yes versus no)
randomization stratiﬁcation variables, usingobserveddatawithout
imputation. In a qualitative, cross-study comparison of BMD gains
in patients treated with romosozumab followed by denosumab in
FRAME compared with those from FREEDOM and its Extension
treated with denosumab alone, all available data at months 6, 12,
18, 24, 36, 48, 60, 72, 96, and 120were used to assessmean change
from baseline in lumbar spine and total hip BMD T-score.
For fracture efﬁcacy, the current analysis focused on the
RRRs in FRAME in the second year alone, when all patients
were treated with the same active therapy—denosumab;
relative fracture risk reductions through month 12 and through
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month 24 of FRAME have been reported.(6) Analyses of new
vertebral fracture endpoints in the second year of FRAME
included all randomized patients who had at least one
radiograph at or prior to the month-12 visit and at least one
radiograph obtained after the month-12 visit. The risk ratio was
determined using the Mantel-Haenszel method, and the
treatment comparison was assessed by a logistic regression
model that was stratiﬁed by age and prevalent vertebral
fracture. Analyses of other fracture endpoints included all
randomized patients who were still on study after the month-12
visit. Treatment comparisons were based on a Cox proportional
hazards model stratiﬁed by age and prevalent vertebral fracture.
Results
Subject disposition
There were 7180 patients in the FRAME study (n¼ 3591 placebo,
n¼ 3589 romosozumab). Baseline characteristics were balanced
between groups and have been described in detail.(6) Overall,
the mean age was 70.9 years, 18.3% of patients had a prevalent
vertebral fracture, and 21.7% of patients had a history of
nonvertebral fracture (Supporting Table 1). Baseline mean BMD
T-score was –2.7 at the lumbar spine, –2.5 at the total hip, and
–2.8 at the femoral neck. For comparative purposes, there were
7808 patients in the FREEDOM study (n¼ 3906 placebo,
n¼ 3902 denosumab), among whom mean age was 72.3 years;
mean BMD T-score was –2.8 at the lumbar spine, –1.9 at the total
hip, and –2.2 at the femoral neck; 23.6% had a prevalent
vertebral fracture; and 38.8% of patients had a history of
nonvertebral fracture (Supporting Table 1).(8)
BMD responder analysis
After 12 months of romosozumab, at the lumbar spine, 96% of
patients achieved gains 3% from baseline, 89% of patients
achieved gains6%, and 68% of patients achieved gains10%,
compared with 22%, 6%, and 1% of patients receiving placebo
achieving these gains (Fig. 1A). Only 1.1% (n¼ 34) of patients
receiving romosozumab failed to increase lumbar spine BMD at
Fig. 1. Percent change in BMD from baseline to month 12 by individual subject. Data are percent change in BMD from baseline to month 12 at the (A)
lumbar spine and (B) total hip. Missing data were imputed by last observation carried forward. The x-axis represents each individual subject. Dotted
horizontal lines reﬂect 3%, 6%, and 10% response relative to baseline. Dotted lines through the plot with arrowheads below the x-axis represent the
percentage of patients with the indicated changes in BMD (0%,3%,6%, and10%). N¼number of patients with values at baseline and at least one
postbaseline visit at or before month 12.
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month 12, with only 0.2% of patients (n¼ 6) having a decline of
3% or more. Among patients who failed to gain BMD, one-half
(52.9%) received fewer than six doses of romosozumab. Among
patients who received placebo, 47% (n¼ 1481) did not increase
BMD at the lumbar spine, and 15.6% (n¼ 490) had a decline of
3% or more.
At the total hip, 78% of patients receiving romosozumab
achieved gains 3% from baseline, 47% of patients achieved
gains 6%, and 16% of patients achieved gains 10%,
compared with 16%, 3%, and 0% of patients receiving placebo
achieving similar gains (Fig. 1B). Six percent (n¼ 189) of patients
receiving romosozumab failed to increase total hip BMD at
month 12, with 1% of patients (n¼ 31) having a decline of 3% or
more. Among patients who failed to gain BMD, 34% (n¼ 62) did
not receive all 12 doses of romosozumab. Among patients who
received placebo, 47% (n¼ 1526) failed to increase BMD, and
12% (n¼ 369) had a decline of 3% or more. BMD response at the
femoral neck was similar to the total hip (data not shown).
Among patients who received romosozumab, 0.4% (n¼ 11) of
patients did not increase BMD at both the lumbar spine and total
hip at month 12. Only one patient had a decline of 3% ormore at
both the lumbar spine and total hip; she had received only four
doses of romosozumab. In contrast, among those receiving
placebo, 26% (n¼ 808) of patients lost BMD at both the lumbar
spine and total hip, and 3% (n¼ 90) had a decline of 3% or more
at both sites.
BMD gains with romosozumab were similar regardless of
baseline age, T-score, or geographic region (data not shown).
BMD T-score changes
Mean (95% CI) change in lumbar spine BMD T-score at month 12
was 0.88 (95% CI, 0.87 to 0.89) for the romosozumab group and
0.03 (95% CI, 0.01 to 0.04) for the placebo group. At month 24,
after both treatment groups received denosumab for 1 year, the
mean change was 1.11 (95% CI, 1.10 to 1.13; romosozumab-to-
denosumab group) and 0.38 (95% CI, 0.36 to 0.39; placebo-to-
denosumab group). Mean (95% CI) change in total hip BMD
T-score at month 12 was 0.32 (95% CI, 0.32 to 0.33) for the
romosozumab group and 0.01 (95% CI, 0.01 to 0.02) for the
placebo group. At month 24, themean change was 0.45 (95% CI,
0.44 to 0.46; romosozumab-to-denosumab group) and 0.17
(95%CI, 0.17 to 0.18; placebo-to-denosumab group). Differences
between groups at both the lumbar spine and total hip were
statistically signiﬁcant at all time points measured (p< 0.001).
FRAME and FREEDOM T-score changes
Next, we qualitatively compared the results in this analysis with
the BMDgains from denosumab, which have been characterized
in the pivotal phase 3 fracture trial, FREEDOM, and its Extension
for up to 10 years of treatment. At the lumbar spine, the
improvements from baseline in BMD T-score observed in
patients treated with romosozumab for 1 year in FRAME were
similar to the BMD gains observed with 4.5 years of continuous
denosumab treatment in the FREEDOM and FREEDOM Exten-
sion studies (Fig. 2A). With the sequence of romosozumab for
1 year followed by denosumab for 1 year, patients from FRAME
achieved BMD T-score gains similar to those observed in
patients from FREEDOM and FREEDOM Extension studies after
7 years of denosumab.
At the total hip, 1 year of romosozumab produced BMD gains
similar to those seen with 3 years of continuous denosumab
treatment (Fig. 2B), and with the sequence of romosozumab for
1 year followed by denosumab for 1 year, patients from FRAME
experienced BMD gains similar to those observed in patients
from FREEDOM after 7 years of denosumab treatment.
Influence of prior romosozumab exposure on fracture
rates during denosumab exposure
In the second year of the FRAME study, when all patients were
receiving denosumab, overall fracture rates were low; ie, lower
than during year 1 in subjects receiving placebo. However, in
year 2, fracture rates were consistently lower in patients who had
received romosozumab in the ﬁrst year compared with those
who had received placebo. Within the second year, for patients
who had received romosozumab ﬁrst, RRRs of fracture were 81%
for vertebral fractures (p< 0.001, Fig. 3A), 32% for clinical
fractures (p¼ 0.052, Fig. 3B), 25% for nonvertebral fractures
(p¼ 0.16, Fig. 3C), 55% for hip fractures (p¼ 0.18, Fig. 3D), 39%
for major osteoporotic fractures (p¼ 0.034), and 32% for major
nonvertebral fractures (p¼ 0.092; Supporting Table 2).
Discussion
Bone mass and structure are main determinants of bone
strength.(9–16) Thus, a treatment approach employing a bone-
forming agent prior to antiresorptive therapy may provide
beneﬁts for patients at high risk for fracture. Indeed, it is
increasingly appreciated that some patients at imminent risk of
fracture—ie, within 1 to 2 years, including those with recent
prior fracture(17–32)—may beneﬁt from this approach. As shown
in the FRAME study, bone-forming therapy with romosozumab
provides an opportunity for rapid bone mass accrual and
structural improvements, demonstrated by BMD gains and
fracture risk reduction observedwithin 1 year of therapy. Indeed,
substantial BMD responses were observed with romosozumab
treatment in FRAME among the majority of patients at the
lumbar spine and total hip, with 96% and 78% of patients
achieving BMD gains of 3% or more from baseline at these sites,
respectively, and larger BMD gains seen in a majority patients.
These BMD increases resulted in large T-score improvements
attained with romosozumab—and romosozumab followed by
denosumab—treatment, withmean changes from baseline over
one full T-score at the lumbar spine and nearly 0.5 at the total hip
after only 2 years. If patients had been treated with denosumab
alone, similar improvements in T-score would have required a
much longer treatment duration. On average, lumbar spine and
total hip BMD gains, with a 2-year treatment sequence of
romosozumab for 1 year followed by denosumab for 1 year,
were comparable to approximately 7 years of treatment with
denosumab alone, the only therapy known to lead to
continuous improvements in BMD, putting the BMD gains
with romosozumab (and romosozumab followed by denosu-
mab) into perspective.
There were fewer fractures in the second year of FRAME
among patients who had received romosozumab ﬁrst. This
difference in fracture rates occurred despite all patients being
treated with denosumab in the second year and despite similar
BMD improvements (both percent change and absolute T-score
increases) in the second year. This observation supports the
notion that achieving a higher BMD with romosozumab
treatment within 1 year not only quickly reduces fracture risk
but also leads to a persistent beneﬁt when transitioning to
antiresorptive therapy. New vertebral and major osteoporotic
fracture incidence showed a signiﬁcant difference between the
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groups in the second year alone, with other fracture types
showing a similar trend, suggesting that a fundamental change
in bone strength occurred during year 1 with romosozumab
treatment prior to antiresorptive therapy. With romosozumab,
that beneﬁt may result from the rapid and substantial bonemass
accrual, achieving more robust bone mass and improved bone
structure prior to transitioning to the follow-on antiresorptive
therapy. In support of this, as has been shown in preclinical
studies, romosozumab administration for 12 months in
ovariectomized cynomolgus monkeys increased cortical and
trabecular bone mass and thickness, and improved bone
strength.(4,5,33) Improvements in cortical thickness and increases
in estimated bone strength of both cortical and trabecular bone
at the spine and hip using CT and ﬁnite element analysis have
also been observed in patients with postmenopausal osteopo-
rosis receiving romosozumab.(34,35)
These data add to our understanding of the value of
administering sequential therapy, starting with a bone-forming
agent, for the treatment of osteoporosis, an increasingly
relevant and important topic in the management of this chronic
condition. It has been documented that the sequence of a bone-
forming agent followed by antiresorptive therapy has the
potential to provide substantially larger BMD improvements
than treatment with an antiresorptive agent ﬁrst.(36) Expanding
on that observation, our current analysis demonstrates that the
sequence of romosozumab followed by denosumab offers
patients a rapid beneﬁt in reducing fracture risk, and then an
additional beneﬁt when receiving an antiresorptive agent such
Fig. 2. BMD T-score increases at the (A) lumbar spine and (B) total hip in FRAME relative to FREEDOM and FREEDOM Extension. aBMD was measured
more frequently (months 6 and 18) in a subset of patients from FRAME who participated in a DXA substudy; additionally, BMDwasmeasured at month 6
in women fromArgentina. bBMDwasmeasuredmore frequently in a subset of patients from FREEDOMwho participated in a DXA substudy. N¼number
of patients with a baseline and at least one postbaseline DXA BMD measurement; n¼number of patients with evaluable data at the time point of
interest.
Journal of Bone and Mineral Research FRAME FOUNDATION EFFECT 1223
as denosumab, as demonstrated by additional reductions in
fracture risk between groups in our study despite the same
follow-on therapy. The sequence of romosozumab followed by
denosumab would allow for BMD gains within a short period of
time not seen previously with other therapeutics.
This sequential approach to osteoporosis treatment may also
be relevant to physicians seeking options for treating to a
T-score target in osteoporosis, because it would allow attain-
ment of the target BMD faster.(37) In addition, although not
directly assessed, the study suggests that absolute BMD is more
relevant as a predictor of fracture risk than change in BMD
(percent or absolute change), as the BMD increases in year 2 of
the study were similar in both groups on denosumab, yet
fracture rates were lower in those who received romosozumab
ﬁrst. Although here we report on 1 year of denosumab following
1 year of romosozumab, ongoing treatment of osteoporosis is
warranted in patients at high risk of fracture; the effects of
romosozumab and denosumab are reversible if discontinued
without follow-on therapy, as has been observed for all
osteoporosis treatments over variable offset timeframes.
This study has a number of strengths, including a
sufﬁciently large sample size to test the study hypothesis,
comparison with placebo treatment during year 1 of the
study, complete data on all study endpoints (including
adjudication of all fractures), and quality control of all BMD
measures. There were also some limitations, including the
post-hoc nature of these analyses without adjustment for
multiple comparisons for the fracture analyses in the second
year alone, and overall low fracture rates in the study limiting
the power to detect between-group differences. However,
the reductions in fracture risk in the second year of FRAME for
patients treated with romosozumab in the ﬁrst year is
consistent with the results of the primary analysis for the
study, in which fracture risk reduction was observed over the
24-month study period for patients who received romoso-
zumab in the ﬁrst year.(6) We were also unable to perform a
quantitative correlation between BMD attained and fracture
rates in the FRAME study because of the low rates of fracture
events in the study available for analysis, particularly in the
second year, as well as the narrow range of T-scores at
baseline and after treatment due to enrollment criteria.
However, previous studies have shown that BMD attained on
therapy correlates with fracture rates,(38) and preclinical data
with romosozumab show that BMD achieved with therapy is
highly correlated with ex vivo bone strength. Last, indirect
comparisons in BMD changes between FRAME and FREEDOM
Fig. 3. Subject incidence of fracture in patients who received placebo-to-denosumab and romosozumab-to-denosumab in FRAME. Subject incidence of
(A) new vertebral, (B) clinical, (C) nonvertebral, and (D) hip fractures during the FRAME study through year 1, through year 2, and during year 2 alone. aRisk
ratio based on Mantel-Haenszel method adjusted for age and prevalent vertebral fracture stratiﬁcation variables; p values were based on a logistic
regressionmodel, adjusting for age and prevalent vertebral fracture stratiﬁcation variables; missing data handled using last observation carried forward.
bHazard ratio and nominal p values were based on a Cox proportional hazards model, adjusting for age and prevalent vertebral fracture stratiﬁcation
variables. Values of p for new vertebral, clinical, nonvertebral, and hip fractures through year 1 and through year 2 were adjusted; p values for new
vertebral, clinical, nonvertebral, and hip fractures in year 2 alone were nominal. RRR¼ relative risk reduction; n/N1¼number of patients with fractures/
number of patients in the analysis set.
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rely on a qualitative comparison across studies; however,
adjusting for key baseline characteristics (eg, baseline BMD,
age, and prevalent vertebral fracture) had no impact on the
conclusions.
Conclusion
One year of treatment with the bone-forming agent romoso-
zumab results in large improvements in BMD, with nearly all
patients responding to therapy, providing a stronger skeletal
foundation and leading to fewer fractures upon transition to
antiresorptive treatment with denosumab. Our data further
support the potential clinical beneﬁt of treatment with
romosozumab and the added beneﬁt of the treatment sequence
of romosozumab followed by denosumab, which may offer
particular value for patients with osteoporosis at imminent risk
of fracture.
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